Efficacy and safety of cladribine addition to induction treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis

References

• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Sigal DS, Miller HJ, Schram ED, et al. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010;116(16):2884–2896.
   PubMed Web of Science ®Google Scholar
• Hołowiecki J, Robak T, Kyrcz-Krzemień S, et al. Daunorubicin, cytarabine and 2-CdA (DAC-7) for remission induction in “de novo” adult acute myeloid leukaemia patients. Evaluation of safety, tolerance and antileukemic activity. Acta Haematol Pol. 2002;33(2):239–247.
   Google Scholar
• Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004;18(5):989–997.
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30(20):2441–2448.
   PubMed Web of Science ®Google Scholar
• Libura M, Giebel S, Piatkowska-Jakubas B, et al. Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. Blood. 2016;127(3):360–362.
   PubMed Web of Science ®Google Scholar
• Wiedower E, Jamy O, Martin MG. Induction of acute myeloid leukemia with idarubicin, cytarabine and cladribine. Anticancer Res. 2015;35(11):6287–6290.
   PubMed Web of Science ®Google Scholar
• Shen Y, Chen J, Liu Y, et al. Addition of cladribine to idarubicin and cytarabine during induction increases the overall efficacy rate in adult patients with acute myeloid leukemia: A matched-pair retrospective comparison. Chemotherapy. 2015;60(5–6):368–374.
   Web of Science ®Google Scholar
• Seligson ND, Hobbs ALV, Leonard JM, et al. Evaluating the impact of the addition of cladribine to standard acute myeloid leukemia induction therapy. Ann Pharmacother. 2018;52(5):439–445.
   PubMed Web of Science ®Google Scholar
• Wrzesien-Kus A, Robak T, Wierzbowska A, et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol. 2005;84(9):557–564.
   PubMed Web of Science ®Google Scholar
• Martin MG, Welch JS, Augustin K, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009;9(4):298–301.
   PubMedGoogle Scholar
• Halpern AB, Othus M, Huebner EM, et al. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. 2018;32(11):2352–2362.
   PubMed Web of Science ®Google Scholar
• Kadia TM, Cortes J, Ravandi F, et al. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. The Lancet Haematology. 2018;5(9):e411–e421.
   PubMed Web of Science ®Google Scholar
• Pluta A, Robak T, Wrzesien-Kus A, et al. Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. Am J Hematol. 2017;92(4):359–366.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Höglund M, Karlsson K, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol. 2003;123(5):810–818.
   PubMed Web of Science ®Google Scholar
• Anzej Doma S, Skerget M, Pajic T, et al. Improved survival of AML patients by addition of cladribine to standard induction chemotherapy. Ann Hematol. 2020;99(3):519–525.
   PubMed Web of Science ®Google Scholar
• Woelich SK, Braun JT, Schoen MW, et al. Efficacy and toxicity of induction therapy with cladribine, idarubicin, and cytarabine (IAC) for acute myeloid leukemia. Anticancer Res. 2017;37(2):713–717.
   PubMed Web of Science ®Google Scholar
• Schoen MW, Woelich SK, Braun JT, et al. Acute myeloid leukemia induction with cladribine: outcomes by age and leukemia risk. Leuk Res. 2018;68:72–78.
   PubMed Web of Science ®Google Scholar
• Seiter K, Ahmed N, Shaikh A, et al. CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients. Leuk Res. 2016;46:74–78.
   PubMed Web of Science ®Google Scholar
• Qasrawi A, Bahaj W, Qasrawi L, et al. Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand? Ann Hematol. 2019;98(3):561–579.
   PubMed Web of Science ®Google Scholar
• Zhou A, Han Q, Song H, et al. Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis. Drug Des Devel Ther. 2019;13:1867–1878.
   PubMed Web of Science ®Google Scholar
• Robak T, Wrzesien-Kus A, Lech-Maranda E, et al. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2000;39(1-2):121–129.
   PubMed Web of Science ®Google Scholar
• Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: A final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80(2):115–126.
   PubMed Web of Science ®Google Scholar